- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06131853
Kinesiophobia in Prostate Cancer
Physical Activity, Fear of Falling, Fatigue and Functionality in Prostate Cancer
This study aimed to investigate the effects of prostate cancer on patients' physical activity, kinesiophobia, fatigue and functionality.
This research is a prospective study to be conducted on volunteer individuals between the ages of 40-75. People diagnosed with prostate cancer (study group) and healthy adults who have not been diagnosed with prostate cancer before (control group) will be included in the study. The demographic characteristics, physical activity levels and quality of life of all individuals participating in the study will be evaluated with an online form. In demographic data, physical, sociodemographic data such as age (years), height (cm), body weight (kg), body mass index (kg/m2) and disease-specific information will be recorded. Physical activity level will be measured with the International Physical Activity Survey short form (UFAA), fatigue with the Functional Evaluation of Chronic Disease Treatment-Fatigue Questionnaire, fear of movement with the Causes of Fear of Movement Questionnaire, and quality of life with the Functional Evaluation of Cancer Treatment-Prostate Version questionnaire (KHTFD-Y).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Selcuklu
-
Konya, Selcuklu, Turkey, 42130
- Selcuk University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
(for prostate cancer-study group)
- Being between the ages of 40-75
- Want to participate in the study
- Being able to read and write
- Being diagnosed with prostate cancer by a specialist physician,
- Being able to provide their mobility independently,
(for healthy controls - control group)
- Being between the ages of 40-75
- Not having any previous cancer history and not having undergone cancer surgery
- Volunteering to participate in the study
Exclusion Criteria:
- Those with a previously known or accompanying diagnosis of dementia
- Not wanting to participate in the study
- The individual has a disease that may prevent him or her from understanding and completing the survey.
- Illiterates
- Those who do not want to participate in the research voluntarily
- Having active metastasis
- Having undergone chemotherapy and radiotherapy in the last 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: control group
|
assessment of physical activity, fatigue, fear of movement, and quality of life
|
|
Experimental: prostate group
|
assessment of physical activity, fatigue, fear of movement, and quality of life
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
International Physical Activity Survey short form
Time Frame: 10 minutes
|
The short form consists of 7 questions.
The form provides information about the frequency and time spent in walking, moderate physical activity, and vigorous physical activity.
|
10 minutes
|
|
Functional Assessment of Fatigue Chronic Disease Treatment-Fatigue Questionnaire
Time Frame: 10 minutes
|
It consists of 13 questions that evaluate the level of fatigue that occurred during daily activities in the last 7 days.
Scoring varies between 0-52.
High scores indicate less fatigue.
|
10 minutes
|
|
Reasons for Fear of Movement Questionnaire
Time Frame: 10 minutes
|
It allows the causes of kinesiophobia to be identified and both biological and psychological causes to be determined separately.
The average of the scores obtained from the biological and physiological subscales gives the total score from the survey.
A 5-point Likert scoring (1 = Totally disagree, 5 = Completely agree) is used in the scale.
An individual's high score from the survey indicates that he/she has more fear of movement.
|
10 minutes
|
|
Functional Evaluation of Cancer Treatment-Prostate Version questionnaire
Time Frame: 10 minutes
|
It consists of 13 questions that evaluate the level of fatigue that occurred during daily activities in the last 7 days.
Scoring varies between 0-52.
High scores indicate less fatigue.
|
10 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/11.09
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on survey evaluation
-
Selcuk UniversityEnrolling by invitation
-
Biruni UniversityCompleted
-
Pamukkale UniversityAkdeniz UniversityCompletedChild, Only | Participation, PatientTurkey
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Breast Carcinoma | Head and Neck Carcinoma | Lung CarcinomaUnited States
-
Sussex Community NHS Foundation TrustNewcastle University; National Health Service, United Kingdom; Brighton & Sussex... and other collaboratorsRecruitingChildren | Patient Satisfaction | Autism | Family | Diagnoses, Syndromes, and ConditionsUnited Kingdom
-
OHSU Knight Cancer InstituteCompletedHead and Neck CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CancerUnited States
-
University of California, San FranciscoNot yet recruitingBreast Cancer | Metastatic Breast Cancer | Carcinoma of the BreastUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hodgkin Lymphoma | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States